PD0325901 is a synthetic orally active MEK1 and MEK2 inhibitor (Ki=1.1 and 0.79, respectively) that research shows inhibits the growth of melanoma cell lines in-vitro and in-vivo. Also inhibits production of VEGF proangiogenic cytokines, and suppresses the phosphorylation of ERK and the RAS/RAF/MEK/ERK signaling pathway, which is frequently active in tumors.